HAE 1Alternative Names: HAE1; PRO 98498
Latest Information Update: 09 Aug 2011
At a glance
- Originator Genentech
- Class Antiasthmatics
- Mechanism of Action IgE receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Allergic asthma
Most Recent Events
- 09 Aug 2008 Discontinued - Phase-II for Allergic asthma in USA (SC)